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expenditures for hepatocellular carcinoma (HCC) among the popu-
lation with urban basic health insurance (BHI) in China. Methods:
Hospitalizations for patients 18 years or older with discharge diag-
nosis of HCC from 2008 to 2011 and enrolled in the Chinese BHI plan
were identiﬁed from the Chinese Health Insurance Research Associ-
ation database. Treatment approaches and hospital expenditures
were assessed for the full sample, and according to city level and
hospital tier. Analyses were extrapolated to the national urban BHI
population. Results: A total of 3679 HCC hospitalizations were
identiﬁed in the period 2008 to 2011, representing 615,359 hospital-
izations among the urban BHI population. More than two-thirds of
the patients received active treatment during hospitalization (68%, N
¼ 418,394), most commonly with traditional Chinese medicine (51%)
and/or transarterial intervention therapy (21%). Cases from larger
level 1 cities and larger tier 3 hospitals reported greater use of active
treatments (81% and 83%, respectively) than did those from smalleree front matter Copyright & 2015, International S
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.1016/j.vhri.2015.03.009
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Carolina at Chapel Hill, 135 Dauer Drive, 1101 Mclevel 3 cities (46%) or tier 1 hospitals (56%). Hospital expenditures
were higher in level 1 cities (mean [95% conﬁdence interval] Chinese
currency renminbi [¥] 17,119 [¥16,292–¥17,946]; US $2,506 [$2,385–
$2,628]) than in level 3 cities (mean [95% conﬁdence interval] ¥7,870
[¥5,775–¥9,964]; $1,152 [$846–$1,459]). Conclusions: Most patients
with HCC received active treatment during hospitalization in China.
There were substantial disparities, however, in the use of HCC
treatments across different economic regions, and nearly a third
received only palliative care. With the recent launch of health care
reform, this study provides valuable insights into current resource
use and costs for HCC in China to help prioritize areas of
improvement.
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Hepatocellular carcinoma (HCC) is one of the most prevalent and
deadly cancers worldwide [1,2]. It is particularly common in Asian-
Paciﬁc countries, resulting from a higher prevalence of hepatitis B
virus infection, andmore than half of all global cases occur in China
alone [3]. In China, HCC is the third most frequent cancer and the
second leading cause of cancer-related death; an estimated 402,000
new cases were diagnosed and 372,000 HCC-related deaths occurred
in 2008 [1]. HCC presents a signiﬁcant economic and societal burden
in China, and it is the highest contributing factor to hospital
expenditures related to hepatitis B virus infection [4–7].In recent years, the China Ministry of Health has declared HCC
as one of ﬁve tumors of high national importance and has
published its newest Diagnosis and Treatment Guidelines for
Primary Liver Cancers (2011 edition) [8]. Largely consistent with
consensus recommendations published by other developed
nations [9–11], guideline-recommended therapeutic options for
HCC are administered on the basis of tumor stage and liver
function [8]. Patients with HCC diagnosed at an early stage are
eligible for curative surgical therapies, which include liver resec-
tion and liver transplantation, and, in some cases, receive local
ablation therapy. Most of the patients, however, are diagnosed
with intermediate to advanced HCC for which curative treatmentociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ment options include palliative resection, local treatments, such
as local ablation and transarterial intervention therapy, radio-
therapy, systemic therapy, and palliative care [8]. Recommended
systemic therapies include molecular targeted therapy, systemic
chemotherapy, as well as traditional Chinese medicine (TCM).
Although multiple treatment options are available, little is
known about current treatment approaches and associated costs
for HCC at the national level in China [12–14]. A better under-
standing of current treatment patterns and expenditures for HCC
using real-world data in China can help guide interventions to
increase compliance with clinical guideline recommendations
and minimize health care costs. Therefore, the objective of this
study was to identify inpatient treatment patterns and health
care expenditures for HCC among the population with urban
basic health insurance (BHI) in China. As secondary objectives,
the study also explored differences in treatment patterns and
associated HCC-related expenditures according to city-level size
and hospital type.
The urban BHI plan is required by the government and
currently covers more than 90% of China’s population in urban
areas nationwide [15]. The urban population in China represents
approximately 51% of the total population in China [16]. Knowl-
edge of HCC treatment patterns and costs among the urban
population can help identify current areas of unmet medical
need across different economic regions and inform current
health care reform efforts to improve long-term outcomes for
this patient population in China.Methods
Study Subjects
Eighteen years or older inpatients with a discharge diagnosis of
HCC from 2008 to 2011 were identiﬁed from the Chinese Health
Insurance Research Association (CHIRA) database. CHIRA con-
ducts a national survey of health care services utilization and
costs for hospitalizations among urban BHI inpatients annually.
For each hospitalization, the integrated database includes infor-
mation on hospital-level characteristics, patients’ demographic
characteristics, health insurance type, and inpatient diagnoses,
procedures, and expenses.
Hospitalizations are selected annually from approximately 60
local health insurance departments using multistage stratiﬁed
sampling in terms of geographic location (East, Central, and
West; excluding Hong Kong, Taiwan, and Macau), city level (levels
1–3), and hospital tier (tiers 1–3). Level 1 cities are deﬁned as
provincial capitals (e.g., Guangzhou, Hangzhou, Nanjing, and
Wuhan) and municipalities (i.e., Beijing, Chongqing, Shanghai,
and Tianjin), level 2 includes prefecture- (e.g., Baoding and
Weihai) and sub–prefecture-level cities (e.g., Jiyuan in Henan),
and level 3 includes the less heavily populated county-level cities
(e.g., Yiwu in Zhejiang). Tier 1 hospitals indicate small commun-
ity hospitals, tier 2 intermediate volume hospitals, and tier 3
large/academic hospital centers.Data Collection
Study inclusion criteria included hospitalizations for individuals
who were 1) 18 years or older, 2) enrolled in the Chinese urban
resident or employee BHI plan, 3) were admitted to a hospital
during the calendar years 2008 to 2011, and 4) had a diagnosis of
HCC at patient discharge. HCC diagnosis was identiﬁed using the
International Classiﬁcation of Diseases, Tenth Revision codes: C22.0
(liver cell carcinoma) and C22.9 (liver, unspeciﬁed) [12].HCC-related treatments were categorized into ﬁve categories
on the basis of China Ministry of Health’s Diagnosis and Treat-
ment Guidelines for Primary Liver Cancers (2011 edition) [8]:
surgical therapy, local therapy, radiotherapy, systemic therapy,
and palliative therapy. Surgical therapies included liver resection
and liver transplant. Local therapies included local ablation
(radiofrequency ablation, microwave ablation, cryoablation,
high-intensity focused ultrasound ablation, and percutaneous
ethanol injection) and transarterial intervention therapy (trans-
catheter arterial infusion chemotherapy, transcatheter arterial
embolization, and transarterial chemoembolization). Systemic
therapies included molecular targeted therapy (sorafenib, suniti-
nib, bevacizumab, cetuximab, and erlotinib), systemic chemo-
therapy (most commonly doxorubucine, gemcitabine, cisplatin,
oxaliplatin, capecitabine, ﬂuorouracil, epirubicin, mitomycin C,
carboplatin, lobaplatin, ﬂoxuridine, and thalidomide, among
others), TCM (e.g., aidi injection, anduolin jiaonang, ankangxin-
jiaonang, antike jiaonang, macao wessing particles, barbadian,
corbrin capsule, shen lian capsule, and chansu injection), and
other systemic therapies (interferon, thymosin α1, and inter-
feron-α). Individuals who did not receive active treatment with
any of the above therapies were categorized as having received
palliative therapy. Palliative therapy was additionally veriﬁed on
the basis of common palliative therapeutic regimens to treat
HCC-related symptoms: narcotic analgesics, nonnarcotic analge-
sics, laxatives, antidiarrhea medications, antihistamines, antide-
pressants, anxiolytics, sedative/hypnotics, oxygen, and others.
To identify all inpatient therapies and procedures, the CHIRA
database contains detailed charge lists for all hospital resources
and related expenditures categorized by service type: diagnostic,
medical device/supply, nursing care, surgical treatment, and
medication. The above-mentioned HCC-related treatments were
identiﬁed and characterized using a combination of records from
the medication, medical device/supply, and surgical treatment
charge lists. Medications for systemic therapies were mapped
using the corresponding Anatomical Therapeutic Chemical Clas-
siﬁcation System codes for each generic name in cases in which
systemic therapies were entered in text [15]. For most treatments,
rather than providing the name of the procedure, the charge list
showed only the device and agents used. Therefore, active treat-
ments were categorized according to detailed device/agent lists
(more than 50,000 items). Physician experts were then asked to
verify the full list for each active treatment category.
Data Analysis and Extrapolation
Descriptive characteristics and treatment patterns for all hospi-
talizations with a discharge diagnosis of HCC were summarized
using frequencies and percentages. Relevant characteristics
included patients’ demographic characteristics (sex, age, and
insurance type), hospital level, city characteristics (city level
and region), and year of hospitalization (2008–2011). Active and
palliative treatment approaches were examined for the full study
sample and according to city level and hospital tier.
Average inpatient hospital expenditures (in Chinese currency
renminbi [¥]) and length of stay (in days) were calculated for all
hospitalizations and across city level. Average hospital expendi-
tures were further analyzed according to the above-mentioned
active and palliative treatment categories. Additional analyses
assessed average BHI reimbursement and cost-sharing for all
hospital expenditures, deﬁned as the ratio of costs for each BHI
reimbursement category (BHI reimbursed, co-payment, and out-
of- pocket costs for treatments ineligible for co-payment) over the
total hospitalization cost for each event, according to year, city
level, and insurance type.
Study analyses were extrapolated to reﬂect the national
population with urban BHI. As exceptions, frequencies and
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approaches were not extrapolated because the sample groups
were too small to provide reliable projections. Two levels of data
projection were conducted to account for the multistage stratiﬁed
sampling design (Table 1). To achieve the target sample size for
each city level, hospitalization records were disproportionately
sampled according to city size using systematic randomized
sampling methods, by the date of patient discharge; 2% of
hospitalization records were selected from level 1 cities, 5% from
level 2 cities, and 10% from level 3 cities. The second level of
projection intends to convert sampled city volume/value to
national level. A city projection factor was recalculated and
applied on a yearly basis on the basis of the population of BHI
enrollees, inpatient volume, as well as annual urban BHI expen-
ditures. Every sampled observation was, in turn, assigned weight-
ing variables according to the total numbers of enrollees and
hospitalizations, total expenditures by health insurance funds,
hospital and city levels, and geographic locations to make
accurate national estimates.
Statistical analyses were conducted using STATA v12 (Stata-
Corp, 2011) and Microsoft Excel (Microsoft, 2010) software. The
Kolmogorov-Smirnov test was conducted to test the normality
assumption for hospital expenditures and length of stay. Both
variables displayed a right-skewed distribution (P 4 0.05 for
normality test); thus, the median and interquartile range were
reported to provide an assessment of dispersion in hospital
expenditures, in addition to the mean and the 95% conﬁdence
interval (95% CI). The mean and the 95% CI in hospital expendi-
tures (in ¥) were approximated to US dollars (US $) using the
World Bank–reported exchange rates for the study period [17].
Comparisons of inpatient treatment approaches, according to
city level and hospital tier, were conducted using chi-square
tests. Differences in hospital expenditures and length of stay
across city levels were assessed on the basis of overlap in the 95%
CIs. Statistical analyses were considered signiﬁcant if P o 0.05.Results
A total of 3679 cases of hospitalizations with a discharge diag-
nosis of HCC were identiﬁed in the period 2008 to 2011, repre-
senting an estimated 615,359 HCC hospitalizations extrapolated
to the national population with urban BHI (Table 2). Most of theTable 1 – Multistage stratiﬁed sampling scheme for cases
for individuals with urban BHI (2008–2011).
Year, city level Total cities, n Sampled cities, n (
2008 646 60 (9.29)
Level 1 31 26 (83.87)
Level 2 249 22 (8.84)
Level 3 366 12 (3.28)
2009 646 50 (7.74)
Level 1 31 24 (77.42)
Level 2 249 15 (6.02)
Level 3 366 11 (3.01)
2010 646 67 (10.37)
Level 1 31 27 (87.10)
Level 2 249 20 (8.03)
Level 3 366 20 (5.46)
2011 646 62 (9.60)
Level 1 31 27 (87.10)
Level 2 249 19 (7.63)
Level 3 366 16 (4.37)
BHI, basic health insurance; HCC, hepatocellular carcinoma.cases were men (79%), between the ages of 40 and 79 years (89%),
and covered under the urban employee BHI plan (83%). Patients
with HCC tended to be hospitalized and treated in larger hospi-
tals; 50% of HCC hospitalizations were from tier 3 and 42% from
tier 2 hospitals. Most of the HCC hospitalizations were from the
more populated and afﬂuent geographical regions in China. An
estimated 40% of the hospitalizations were from level 1 (n ¼
243,176) and 43% from level 2 (n ¼ 267,255) cities, and 61% (n ¼
377,966) were from Eastern China.
HCC Treatment Patterns
More than two-thirds of the patients received active treatment
during hospitalization (68%, n ¼ 418,394), whereas the remaining
received palliative therapy (Table 3). Among active treatments,
most patients received systemic therapy (63%, n ¼ 386,624) or
local therapy using transarterial interventions (21%, n ¼ 130,511);
use of curative surgical treatments (2%) or radiotherapy (2%) was
rather limited. TCM was the most common systemic therapy,
administered at approximately half of all hospitalizations (51%,
n ¼ 313,056), followed by other systemic therapies (24%, n ¼
150,092) and chemotherapy (16%, n ¼ 98,175). TCM was generally
administered in combination with other active treatments (61%),
and less commonly used alone (data not shown).
There were substantial and highly signiﬁcant differences in
treatment patterns across city level and hospital tier, after
extrapolation to the national level (Table 4; all comparisons P o
0.0001). Cases from the more heavily populated level 1 cities
reported the greatest use of active treatments (81%), whereas
only 46% of the cases from level 3 cities received active treatment
(P o 0.0001). Level 1 cities also showed higher use of local
therapies (35%) and surgical treatments (3%) than did level 3
cities (local therapies 9%; surgical treatments 1%). Statistically
signiﬁcant differences in the use of treatment approaches were
also observed across hospital tiers (all P o 0.0001). A greater
number of HCC cases treated at larger tier 3 hospitals received
active treatment (83%) compared with those treated in smaller
tier 1 hospitals (56%).
Across all HCC hospitalizations, approximately 41% of the
patients who received active treatment during hospitalization
received only one therapy, whereas the remaining were treated
using combination therapies (Table 5, numbers represent the
study sample). TCM was commonly used as a supplementaryof HCC-related hospitalizations according to city level
%) Total hospitalizations, n HCC cases, n (%)
98,979 589 (0.60)
48,845 366 (0.75)
38,799 180 (0.46)
11,335 43 (0.38)
157,577 876 (0.56)
100,074 598 (0.60)
48,720 253 (0.52)
8,783 25 (0.28)
236,366 1283 (0.54)
152,476 909 (0.60)
64,219 305 (0.47)
19,671 69 (0.35)
375,822 931 (0.25)
245,707 634 (0.26)
112,023 292 (0.26)
18,092 5 (0.03)
Table 2 – Patient and demographic characteristics among cases of HCC-related hospitalizations, extrapolated to
reﬂect HCC hospitalizations among the national population with urban BHI (2008–2011).
Characteristic Sample (n ¼ 3679) Estimated urban hospitalizations (n ¼ 615,359)
Cases % Cases %
Sex
Male 2876 78.17 487,011 79.14
Female 803 21.83 128,348 20.86
Age group (y)
18–39 221 6.00 32,860 5.34
40–59 1677 45.58 285,106 46.33
60–79 1574 42.79 267,274 43.43
Z80 194 5.27 26,866 4.37
Unspeciﬁed 13 0.35 3,252 0.53
Insurance type
Urban employee 3186 86.60 511,255 83.08
Urban resident 446 12.12 81,700 13.28
Unspeciﬁed 47 1.28 22,403 3.64
Hospital tier
3 2460 66.87 307,546 49.98
2 956 25.99 260,459 42.33
1 241 6.55 45,603 7.41
Unspeciﬁed 22 0.60 1,751 0.28
City level
1 2507 68.14 243,176 39.52
2 1030 28.00 267,255 43.43
3 142 3.86 104,928 17.05
Region
East 2590 70.40 377,966 61.42
Central 566 15.38 166,019 26.98
West 523 14.22 71,374 11.60
Year
2008 589 16.01 144,036 23.41
2009 876 23.81 149,001 24.21
2010 1283 34.87 147,586 23.98
2011 931 25.31 174,736 28.40
BHI, basic health insurance; HCC, hepatocellular carcinoma.
Table 3 – Inpatient treatment approaches among cases of HCC-related hospitalizations, extrapolated to reﬂect
HCC hospitalizations among the national population with urban BHI (2008–2011).
Treatment approaches* Sample (n ¼ 3679) Estimated urban hospitalizations (n ¼ 615,359)
Cases % Cases %
Active treatment 2907 79.02 418,394 67.99
Systemic therapy 2672 72.63 386,624 62.83
TCM 2173 59.06 313,056 50.87
Chemotherapy 618 16.80 98,175 15.95
MTD therapy 10 0.27 † †
Others 1231 33.46 150,092 24.39
Local therapy 1148 31.20 150,106 24.39
TAI therapy 988 26.86 130,511 21.21
Local ablation 223 6.06 27,474 4.46
Surgical treatment 148 4.02 12,214 1.98
Liver resection 147 4.00 12,191 1.98
Liver transplant 1 0.03 † †
Radiotherapy 107 2.91 13,233 2.15
Palliative therapy 772 20.98 196,965 32.01
BHI, basic health insurance; HCC, hepatocellular carcinoma; MTD, molecular targeted drug; TAI, transarterial intervention; TCM, traditional
Chinese medicine.
* Treatment categories are based on the Diagnosis and Treatment Guidelines for Primary Liver Cancers (2011 edition), published by the China
Ministry of Health [4].
† Indicates that the sample size was too small for data extrapolation at the national level of estimated urban hospitalizations.
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Table 4 – Comparisons of inpatient treatment approaches among cases of HCC-related hospitalizations across city level and hospital tier, extrapolated
to reﬂect HCC hospitalizations among the national population with urban BHI (2008–2011)
Treatment approaches* City level† Hospital tier†‡
Level 1
(n ¼ 243,176)
Level 2
(n ¼ 267,255)
Level 3
(n ¼ 104,928)
Tier 1
(n ¼ 45,603)
Tier 2
(n ¼ 260,459)
Tier 3
(n ¼ 307,546)
Cases % Cases % Cases % Cases % Cases % Cases %
Active treatment 197,604 81.26 172,524 64.55 48,266 46.00 25,434 55.77 135,776 52.13 255,712 83.15
Systemic therapy 181,949 74.82 159,793 59.79 44,882 42.77 24,943 54.70 127,314 48.88 232,911 75.73
TCM 150,116 61.73 122,178 45.72 40,762 38.85 21,986 48.21 97,374 37.39 192,487 62.59
Chemotherapy 42,763 17.59 47,663 17.83 7,749 7.38 4,864 10.67 37,047 14.22 55,402 18.01
MTD therapy 445 0.18 628 0.24 0 0.00 0 0.00 446 0.17 628 0.20
Others 83,737 34.43 51,960 19.44 14,395 13.72 7,105 15.58 37,028 14.22 105,589 34.33
Local therapy 84,737 34.85 55,923 20.92 9,445 9.00 4,085 8.96 37,241 14.30 108,130 35.16
TAI therapy 69,990 28.78 51,076 19.11 9,445 9.00 3,275 7.18 34,990 13.43 91,844 29.86
Local ablation 20,793 8.55 5,811 2.17 870 0.83 1,080 2.37 3,337 1.28 22,811 7.42
Surgical treatment 8,419 3.46 2,569 0.96 1,225 1.17 128 0.28 1,725 0.66 10,343 3.36
Liver resection 8,397 3.45 2,569 0.96 1,225 1.17 128 0.28 1,725 0.66 10,321 3.36
Liver transplant 22 0.01 0 0.00 0 0.00 0 0.00 0 0.00 22 0.01
Radiotherapy 6,751 2.78 6,038 2.26 444 0.42 128 0.28 2,416 0.93 10,566 3.44
Palliative therapy 45,573 18.74 94,731 35.45 56,661 54.00 20,169 44.23 124,683 47.87 51,834 16.85
BHI, basic health insurance; HCC, hepatocellular carcinoma; MTD, molecular targeted drug; TAI, transarterial intervention; TCM, traditional Chinese medicine.
* Treatment categories are based on the Diagnosis and Treatment Guidelines for Primary Liver Cancers (2011 edition), published by the China Ministry of Health [4].
† Statistical comparisons of inpatient treatment approaches were highly signiﬁcant across both city level (all P o 0.0001) and hospital tier (all P o 0.0001) groups.
‡ A total of 22 cases (N ¼ 1751 after extrapolation) were excluded because of missing hospital status information.
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Table 5 – Distribution of treatment approaches and hospital expenditures among cases of HCC-related
hospitalizations (2008–2011).*
Treatment approaches Sample (n ¼ 3679) Hospital expenditures
Cases % Mean (95% CI) (¥) Median (IQR) (¥) Mean (95% CI) (US $)
Palliative therapy 772 20.98 9,295 (7,956–10,633) 4,685 (7,161) 1361 (1165–1557)
Active treatment 2907 79.02 18,432 (17,662–19,202) 13,054 (15,406) 2699 (2586–2811)
Monotherapy 1187 40.83 12,544 (11,821–13,267) 8,977 (10,934) 1837 (1731–1942)
Systemic therapy 977 82.31 11,805 (11,004–12,606) 7,792 (10,486) 1728 (1611–1846)
TCM 681 57.37 11,408 (10,478–12,338) 7,611 (9,444) 1670 (1534–1806)
Chemotherapy 81 6.82 10,736 (8,357–13,115) 8,019 (7,363) 1572 (1224–1920)
Others 215 18.11 13,465 (11,515–15,415) 8,489 (14,653) 1971 (1686–2257)
Local therapy 180 15.16 14,279 (12,775–15,783) 11,946 (7,737) 2091 (1870–2311)
TAI therapy 151 12.72 13,575 (12,084–15,066) 11,554 (6,715) 1988 (1769–2206)
Local ablation 29 2.44 17,942 (12,684–23,200) 16,846 (12,541) 2627 (1857–3397)
Surgical resection 14 1.18 30,110 (19,941–40,279) 22,181 (10,599) 4408 (2920–5897)
Radiotherapy 16 1.35 22,785 (16,048–29,522) 21,878 (22,479) 3336 (2350–4322)
Combination therapy 1720 59.17 22,495 (21,332–23,658) 16,415 (16,401) 3294 (3123–3464)
TCM þ OST 344 20.00 16,339 (14,664–18,014) 10,719 15,857) 2392 (2147–2637)
TCM þ TAI 253 14.71 16,559 (15,272–17,845) 14,908 (9,502) 2424 (2236–2613)
TCM þ TAI þ OST 202 11.74 25,395 (22,402–28,387) 19,728 (12,483) 3718 (3280–4156)
TCM þ Chemo 154 8.95 10,958 (9,541–12,374) 8,647 (7,258) 1604 (1397–1812)
TCM þ Chemo þ OST 102 5.93 23,639 (15,144–32,135) 12,202 (17,280) 3461 (2217–4705)
TCM þ TAI þ Chemo 71 4.13 26,451 (18,809–34,092) 18,175 (12,363) 3873 (2754–4992)
TAI þ OST 69 4.01 16,824 (14,650–18,999) 14,843 (11,068) 2463 (2145–2782)
TCM þ TAI þ Chemo þ OST 57 3.31 33,301 (27,121–39,480) 25,523 (34,878) 4876 (3971–5780)
TCM þ Local ablation 42 2.44 23,473 (18,242–28,703) 21,225 (16,218) 3437 (2671–4202)
Chemo þ OST 36 2.09 17,149 (11,309–22,989) 9,758 (13,879) 2511 (1656–3366)
Other combinations 390 22.67 33,623 (30,441–36,805) 24,620 (22,202) 4923 (4457–5389)
Chemo, chemotherapy; CI, conﬁdence interval; HCC, hepatocellular carcinoma; IQR, interquartile range; OST, other systemic therapy; TAI,
transarterial intervention; TCM, traditional Chinese medicine.
* Data were not extrapolated to the national level of estimated urban hospitalizations because many of the sample groups were too small.
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other systemic therapy (20%) or transarterial intervention
therapy (15%).
HCC Hospital Expenditures
Average health care expenditures for all HCC-related hospital-
izations were ¥13,467 (95% CI ¥12,873–¥14,060; $1,972 [$1,885–
$2,059]) (Table 6). Median hospital expenditures were substan-
tially lower than the median with a high level of dispersion
(¥8,573; interquartile range ¥12,089), indicating a right-skewed
distribution in health care costs. Hospital expenditures were
substantially higher in level 1 (mean [95% CI] ¥17,119 [¥16,292–
¥17,946]; $2,506 [$2,385–$2,628]) than in level 3 (¥7,870 [¥5,775–Table 6 – Hospital expenditures and length of stay amon
city level, extrapolated to reﬂect HCC hospitalizations am
615,359).
Hospital expenditures
City level Mean
(95% CI) (¥)
Median (IQR) (¥) % C
All 13,467 (12,873–14,060) 8,573 (12,089)
1 17,119 (16,292–17,946) 12,013 (15,722)
2 12,341 (11,311–13,370) 8,489 (10,223) 
3 7,870 (5,775–9,964) 4,560 (5,126) 
BHI, basic health insurance; CI, conﬁdence interval; HCC, hepatocellular
* Represents the % change in mean costs, in reference to city level 1 cat¥9,964]; $1,152 [$846–$1,459]) cities, largely reﬂecting the higher
adoption rate of active treatments in the more developed regions.
In contrast, length of stay did not signiﬁcantly differ according to
city level, indicated by the overlap in the 95% CIs for length of
stay across city levels.
Mean hospital expenditures were substantially lower for
individuals who received palliative therapy (¥9,295 [¥7,956–
¥10,633]; $1,361 [$1,165–$1,557]) than for those who received
active treatment during hospitalization (¥18,432 [¥17,662–
¥19,202]; $2,699 [$2,586-$2,811]) (Table 5). Among single active
treatment approaches, average hospital expenditures for cases
involving surgical resection (¥30,110 [¥19,941–¥40,279]; $4,408
[$2,920–$5,897]) and radiotherapy were the highest (¥22,785
[¥16,048–¥29,522]; $3,336 [$2,350–$4,322]), whereas hospitalg cases of HCC-related hospitalizations by year and
ong the national population with urban BHI (N¼
Length of stay (d)
hange* Mean (95% CI)
(US $)
Mean
(95% CI)
Median (IQR)
1972 (1885–2059) 18 (17–19) 13 (15)
2506 (2385–2628) 18 (17–18) 13 (13)
27.91 1807 (1656–1958) 18 (17–19) 13 (16)
54.03 1152 (846–1459) 19 (16–22) 12 (21)
carcinoma; IQR, interquartile range.
egory.
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(¥11,805 [¥11,821–¥13,267]; $1,728 [$1,611–$1,846]). Average hospi-
tal expenditures for individuals who received multiple treat-
ments during hospitalization were proportionately higher
(¥22,495 [¥21,332–¥23,658]; $3,294 [$3,123–$3,464]), mainly reﬂect-
ing the added cost of the supplemental medical devices/supplies.
The most common combination therapies involved the use of
TCM as a supplement to other systemic treatment or transarterial
intervention therapy, with average hospital expenditures totaling
¥16,339 (95% CI ¥14,664–¥18,014; $2,392 [$2,147–$2,637]) and
¥16,559 (95% CI ¥15,272–¥17,845; $2,424 [$2,236–$2,613]),
respectively.
BHI Reimbursement and Cost-Sharing
Most of the health care expenditures related to HCC hospital-
izations were covered under the BHI plan (80%), and the remain-
ing were paid out of pocket (9%) or through co-payments (11%)
(Fig. 1). The ratio of BHI coverage ﬂuctuated slightly over time
(range 75%–86%), but co-payments generally remained consistent
(range 8%–10%). Interestingly, hospitalizations from level 2 cities
had the highest ratio of BHI coverage (85%) and the lowest ratio of
out-of-pocket costs (6%), whereas those from level 1 cities had a
much higher ratio of out-of-pocket expenses (18%). Trends in the
BHI reimbursement ratios were consistent for individuals covered
under employee versus resident BHI plans.Discussion
HCC is one of the most common and deadly cancers in East Asia,
and China alone contributes more than half of all cases world-
wide [3,18]. The China Ministry of Health has made great strides
to improve the clinical management of HCC [8]; yet, little is
known about current treatment approaches and associated costs
in China [12–14]. The present study examined treatment patterns
and health care expenditures for more than 3600 cases of HCC
hospitalizations among the national population with urban BHI
in China, representing more than 615,000 cases of HCC hospital-
izations in the period 2008 to 2011. The results revealed that theFig. 1 – Average HCC-related hospital expenditures and BHI reim
extrapolated to reﬂect HCC hospitalizations among the national
insurance; HCC, hepatocellular carcinoma. *Reﬂects the ratio of
mean total costs of hospitalization. †Insurance type was unspeci
in the study sample.large majority received active treatment during hospitalization;
however, nearly a third received only palliative care.
The results showed substantial disparities in the use of active
treatments across different economic regions in China (all com-
parisons P o 0.0001). More than 80% of the HCC cases from the
heavily populated provincial capital and provincial-level cities
(level 1) received active treatment during hospitalization, com-
pared with only 46% of the cases from county-level cities (level 3).
As a result, average hospital expenditures were substantially
higher in level 1 (mean ¥17,119; $2,506) than in level 3 (mean
¥7,870; $1,152) cities, largely reﬂecting the higher adoption rate of
active treatments.
Systemic and local therapies were the most common active
treatments for HCC, administered at approximately 63% and 21% of
hospitalizations, respectively. However, overall use of curative
surgical treatments, including liver resection and liver transplant,
was quite rare (2%). To some extent, the infrequent use of surgical
treatments may reﬂect variations in availability across different
geographic and economic regions in China, differences in hospital-
level expertise, and an overall shortage in liver transplant donors.
To a greater extent, however, these trends reﬂect the current reality
where most patients are diagnosed in the advanced stages when
surgical treatment is no longer an option [12]. Further research,
using databases with more detailed information on tumor size and
liver function at diagnosis, is needed to better understand whether
patients with HCC who are clinically eligible for surgical treatment
are not receiving guideline-recommended care.
TCM was the most commonly used therapy, administered at
approximately half of all hospitalizations. According to current
guideline recommendations in China, TCM is considered to be a
useful and relatively low-cost supplemental therapy to reduce
discomfort from treatment-related adverse effects and HCC-
related symptoms [8]. Use of TCM as the primary treatment is
generally not recommended because of a lack of clinical trial
evidence suggesting clinical effectiveness. Consistent with guide-
line recommendations, TCM was generally used as a supplemen-
tal therapy, primarily in combination with other systemic
therapy or transarterial intervention therapy, and less commonly
used alone (39%). Use of TCM in combination with other treat-
ments had a relatively modest impact on average hospital costs.bursement ratios* by year, city level, and insurance type,
population with urban BHI (N ¼ 615,359). BHI, basic health
mean costs for each BHI reimbursement category over the
ﬁed for n ¼ 47 cases of HCC-related hospitalizations included
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from previous studies estimating the clinical impact of HCC in
China. As noted in population-based studies of HCC incidence in
China [3], most of the HCC cases in the present study were men,
older than 40 years, and clustered in the more populated regions
of China. A previous study of inpatient treatment patterns among
patients with HCC treated across 10 hospital sites in China from
1996 to 1998 also found that approximately 29% of the patients
received local therapies during hospitalization and use of radio-
therapy was limited (0.7%) [12]. However, the study found that
more than 46% of the patients received surgical resection,
compared with only 2% of the patients in the present study. In
interpreting these results, however, it is important to note that
most of the HCC cases were identiﬁed from three large provincial
hospitals in Shanghai, Guangzhou, and Nanning (n ¼ 2659, 82%)
[12]. As a result, patients treated at these hospitals may have had
greater access to surgical technologies than did the broader
population of patients with HCC in China. Further research is
needed to understand whether the current trends in HCC treat-
ment approaches observed in this study can be replicated using
other large-scale databases.
To our knowledge, no other studies have assessed hospital
expenditures related to HCC treatment using a large and repre-
sentative sample of HCC cases in China. One small database
study assessed direct and indirect costs of HCC among individ-
uals with chronic hepatitis B diagnosed with HCC in Beijing (n ¼
53) and Guangzhou (n ¼ 48) [14]. The study found that average
hospital expenditures in the period 2006 to 2007 for patients with
HCC treated in a tier 3 hospital ranged from $2,638 (¥20,075; 7.61
¥/US $ for 2007 [17]) to $3,370 (¥25,646) in Beijing and Guangz-
hou, respectively. In the present study, average hospital expen-
ditures for level 1 cities were generally similar (mean [95% CI]
¥17,119 [¥16,292–¥17,946]; $2,506 [$2,385–$2,628]). The study fur-
ther analyzed average annual outpatient treatment costs, which
totaled $1,251 (¥9,520) in Beijing and $868 (¥6,605) in Guangzhou
[14]. Unfortunately, the CHIRA database did not contain informa-
tion on outpatient services; however, these costs are compara-
tively low, representing approximately 20% of the total annual
direct costs associated with HCC management in China [14].
This study provides valuable insights into current treatment
practices and associated hospital expenditures among the pop-
ulation with urban BHI in China, which currently covers more
than 90% of China’s population in urban areas nationwide [15].
Nonetheless, the study does not capture HCC treatment patterns
among the rural population in China, which represent nearly half
(49%) of the total population in China [16]. Even in urban areas,
this study found substantial disparities in the use of HCC treat-
ments across city levels and hospital tiers. Previous research
suggests that health care inequities are even larger in rural areas
[19]. In the present study, the urban BHI reimbursed approxi-
mately 75% to 80% of inpatient expenditures for each hospital-
ization related to HCC in the period 2008 to 2011, whereas
previous research suggests that individuals from rural areas are
generally either uninsured or underinsured [15,19]. Although
research conducted in rural areas of Qidong has identiﬁed
improvements in survival disparities in comparison to developed
regions, there is still a need for improving earlier detection and
access to curative treatments [18].
Recognizing the wide socioeconomic inequities in health care
coverage and access, China has launched its health care reform
plan to ensure universal and affordable health coverage by 2020
[15]. Initiated in April 2009, the plan aims to expand health care
coverage to more than 90% of the population, establish a national
essential medicines system, improve the primary care delivery
system, expand public health services, and pilot public hospital
reforms [15,20]. Already, the program has expanded the role of
primary care providers, established national formulary lists tocurb drug spending, and has initiated pilot programs in 16 cities
to reform hospital governance and improve quality and efﬁciency
of care [15]. Since 2011, policies have also identiﬁed priority
diseases, including cirrhosis and cancer, for further reductions
in co-payments. With these remarkable systemwide improve-
ments, the climate surrounding the clinical management of HCC
will likely change in the near future. The results of this study
highlight current disparities in access to active treatment
approaches for HCC in China, particularly across city levels and
hospital tiers, to help prioritize areas of improvement.
Although the results of this study provide valuable insights into
current resource use and costs associated with HCC in China, it has
certain limitations: 1) As previously mentioned, the study database
exclusively captured services provided during each hospitalization
among individuals with urban BHI for each year, and does not
capture outpatient treatments or any services provided in rural
areas. In particular, molecular targeted drugs, such as sorafenib, can
be purchased outside the hospital; as a result, this study may
underestimate the use of these drugs. 2) Although the annual
CHIRA surveys are designed to be representative of the urban BHI
population through both multistage stratiﬁed sampling and sys-
tematic sampling methods, the annual samples are small relative
to the extrapolated population and, as yet, there is no validation or
comparison between the sampled and nonsampled populations. 3)
In addition, because of database proﬁle and availability, the study is
based on event-level data (i.e., hospitalization), not patient-level
data. As a result, the database does not capture the entire treatment
course for patients who are readmitted to the hospital for HCC
treatment. 4) Because the study surveyed data from hospital charge
lists, systematic misclassiﬁcation of devices and procedures across
surveyed hospital sites may have occurred. To minimize this
possibility, hospital charge lists were reviewed on a case-by-case
basis, using a comprehensive device/agent list of more than 50,000
items to facilitate treatment classiﬁcation. 5) Last, the use of the
International Classiﬁcation of Diseases, Tenth Revision, Clinical Modiﬁca-
tion code of C22.9 (Malignant neoplasm of liver, not speciﬁed as
primary or secondary) might overestimate the number of HCC-
related hospitalizations because it includes other more rare cases of
liver cancer unrelated to hepatocellular carcinoma.
In conclusion, among the population with urban BHI in China,
approximately two-thirds of the patients diagnosed with HCC in
the period 2008 to 2011 received active treatment during hospital-
ization and average inpatient expenditures were more than
¥13,000 ($1900). Only 2% of all patients with HCC received
curative surgical treatments during hospitalization, indicating
that patients were generally diagnosed in the more advanced
stages. TCM was the most commonly used therapy, administered
at approximately half of all hospitalizations, and was mainly
used in combination with other HCC treatments. There were
substantial disparities in the use of HCC treatments across
different city levels and hospital tiers in China. As a result,
hospital expenditures were considerably higher in the more
developed regions. With the recent launch of health care reform
in China, the landscape surrounding HCC management will likely
change in the near future. The results of this study provide
valuable insights into current resource use and costs for HCC, as
well as treatment disparities, to help prioritize areas of
improvement.
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